This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.
/ / /
/ / /

For healthcare professionals only

You are viewing the Novo Nordisk Virtual platform, provided to non-US health care professionals from around the world. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional.

 

This site is not country-specific and therefore may contain information which is not applicable to your country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.

 

This site is not intended to provide medical advice and/or treatment guidance. Novo Nordisk accepts no liability for the accuracy, completeness or use of the information, and disclaims any liability to update the information contained on this site.

I hereby declare I am a non-US health care professional and that I have read and agreed to the terms mentioned above.

Scroll down

Sogroya®

Sogroya® is a once-weekly growth hormone therapy for paediatric patients with growth hormone deficiency.1
Norditropin®

We’re Aiming Higher to Meet Your Expectations.2

More Than Height

At Novo Nordisk, we are committed to raise awareness for growth disorders and educate the population on the importance of Growth through the growth calculator on MoreThanHeight. How growth calculator can support growth monitoring in children?
More Than Height

At Novo Nordisk, we are committed to raise awareness for growth disorders and educate the population on the importance of Growth through the growth calculator on MoreThanHeight. How growth calculator can support growth monitoring in children?

Living with a growth disorder can cause a lot of emotional distress, just like the path to diagnosis can be challenging and long. Get a firsthand insight from patients and their families about what it means to live with a growth disorder.
Patient perspectives on growth disorder
Patient perspectives on growth disorder

Living with a growth disorder can cause a lot of emotional distress, just like the path to diagnosis can be challenging and long. Get a firsthand insight from patients and their families about what it means to live with a growth disorder.

Scientific content at ENDO 2024

Discover all our scientific content for ENDO on Science hub, featuring our scientific presentations, recordings, and the complete programme, and much more.
Growth disorder

Read the most recent articles and congress materials including upcoming congresses related to growth disorder.

1.

Sogroya® Summary of Product Characteristics. 2022:1-92.

2.

Norditropin® Summary of Product Characteristics. 2022.

3.

Boycott, K., Ardigó, D. Addressing challenges in the diagnosis and treatment of rare genetic diseases. Nat Rev Drug Discov 17, 151–152 (2018). https://doi.org/10.1038/nrd.2017.246

3.

Boycott, K., Ardigó, D. Addressing challenges in the diagnosis and treatment of rare genetic diseases. Nat Rev Drug Discov 17, 151–152 (2018). https://doi.org/10.1038/nrd.2017.246

 

The information contained in this site is intended for healthcare professionals only outside of the United States of America. This site is not intended to provide medical advice and/or treatment guidance. Only a physician can determine whether a specific product is correct for a particular patient. This site is not country-specific and therefore may contain information which is not applicable to your country. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional. Any images shown on the page are a mix of models and real patients.

 

HQ24NORD00004, May 2024

Novo Nordisk Healthcare AG, Zurich, Switzerland